Home
NewsNewsThe Relocation of Westminster Fertility Clinic to Long Beach by RPMG will expand access and improve specialized services for the Southern California region.
Reproductive Partners Medical Group - RPMG, a nationally respected leader in fertility care and family building, is part of the nationally recognized fertility care network, Ivy Fertility, has announced the relocation of Westminster fertility clinic to a newly designed and patient-focused facility that is complete with a lab as well as a surgery center based in California’s Long Beach.
The move is made to better serve patients based across greater Los Angeles as well as Orange County with enhanced access, care, and continuity and also an upgraded clinic experience that is grounded in scientific excellence along with individualized support. It is well to be noted that for over three decades, RPMG has in fact stood right at the forefront of fertility medicine, enabling individuals and also couples having diverse backgrounds to attain their dreams of parenthood by way of comprehensive services such as IVF, IUI, genetic testing, fertility preservation, and LGBTQ+ family building, as well as advanced reproductive care.
This kind of move goes on to represent more than just a change of address. It is indeed a step forward in how one goes on to deliver care with empathy along with clinical excellence at every stage, remarked the board-certified reproductive endocrinologist with Reproductive Partners Medical Group, Marli Amin, MD. Dr. Amin goes on to bring her expertise within IVF, egg freezing, IUI along with comprehensive fertility testing and also customized patient guidance, to the heart of this new location.
Besides setting up this gorgeous new clinic infused with a lab as well as a surgery center by relocating the Westminster fertility clinic, the Long Beach clinic is also going to provide the same trusted as well as evidence-based treatment plans, and along with it, continuity of care, which the patients have come to depend on, delivered by the world-class team of fertility experts along with the clinical support staff of RPMG.
The fact is that moving to Long Beach highlights their dedication to widening their access without compromising on the customized attention that their patients expect, said the Chief Operating Officer of Reproductive Partners Medical Group, Christina Westbrook. The present patients are going to continue receiving uninterrupted care, and the new patients are invited to have scheduled consultations at the Long Beach setup. The operational hours and contact information, along with support services, remain synced with the commitment to responsive and patient-centered service of RPMG.
A groundbreaking Nature Medicine study compares AI deep learning against expert embryologists in selecting embryos. While pregnancy rates remain comparable, the study uncovers a massive advantage in efficiency that could revolutionize IVF labs worldwide. Discover how AI-driven embryo selection accuracy is reshaping the future of fertility treatment.
FertilAI has received EU MDR clearance for tools advancing Predictive AI in Fertility through its Fertilane platform. StimAI and OvuPredict help clinicians optimise IVF timing, predict ovulation and improve scheduling efficiency. The technology supports scalable fertility care, reduced monitoring needs and better patient treatment experiences globally.
The Ferring Global Fertility Monitor has been launched by Ferring Pharmaceuticals and Gallup to examine fertility trends in 70 countries. Through large-scale surveys, the project will explore economic, social, and cultural influences on parenthood decisions. Insights are expected to guide policy, healthcare planning, and future demographic strategies.
Maven Clinic has expanded its Fertility and Family Building program with earlier diagnostics, wearable integration, and AI-powered personalised care. The enhanced platform supports faster diagnosis, improved treatment decisions, and condition-specific pathways for PCOS, endometriosis, and oncofertility. The rollout continues through 2026 with added innovations and partnerships.
Germany is debating the legalization of egg donation in Germany, challenging decades-old restrictions under the Embryo Protection Act. Experts argue reform is overdue to align with modern reproductive science, reduce fertility tourism, and improve patient care, while policymakers work to balance ethical concerns with growing demand for advanced fertility treatments.
A new review highlights the link from Forever Chemicals to reduced ART outcomes, showing how PFAS exposure impacts fertility, pregnancy, and reproductive health. The findings raise urgent concerns for IVF patients and call for stronger regulation, deeper research, and systemic action to address environmental risks in reproductive medicine.
The 2027 Title X NOFO introduces a major policy shift toward addressing infertility crisis in the U.S. It mandates basic infertility services, expands male reproductive health focus, and promotes education on body literacy and lifestyle factors, aiming to support family formation alongside traditional contraceptive services.
